Table 2 Univariate analyses of predictors for radiographic progression

Treatment with adalimumab^a

NA

NA

NA

NA

NA

NA

0.24

0.13, 0.48

< 0.001

CRP (time-averaged)

1.74

1.33, 2.28

< 0.001

1.48

0.99, 2.22

0.058

1.84

1.47, 2.30

< 0.001

CRP (continuous)

1.40

1.12, 1.75

0.003

1.05

0.84, 1.31

0.684

1.18

1.03, 1.35

0.017

CRP > 0.287 mg/dl^a

5.50

1.59, 19.09

0.007

3.12

0.39, 25.02

0.285

4.25

1.47, 12.24

0.007

CRP (1.0 mg/dl^a

3.98

1.90, 8.32

< 0.001

3.51

1.08, 11.39

0.036

3.82

2.09, 6.99

< 0.001

CRP (2.0 mg/dl^a

4.40

2.05, 9.45

< 0.001

1.34

0.34, 5.23

0.676

3.46

1.87, 6.42

< 0.001

Age

1.00

0.97, 1.03

0.954

1.02

0.97, 1.07

0.399

1.01

0.98, 1.04

0.484

RF-positive^a

1.45

0.46, 4.60

0.530

1.65

0.33, 8.27

0.542

1.41

0.57, 3.49

0.458

Swollen joint count

1.02

0.99, 1.06

0.122

1.01

0.97, 1.06

0.657

1.02

1.00, 1.04

0.100

Tender joint count

1.00

0.98, 1.02

0.741

1.01

0.98, 1.04

0.459

1.01

0.99, 1.02

0.358

mTSS

1.03

1.01, 1.04

< 0.001

1.00

0.995, 1.01

0.365

1.01

1.00, 1.02

0.001

Joint erosion

1.05

1.02, 1.08

< 0.001

1.01

0.99, 1.02

0.490

1.02

1.01, 1.03

0.001

Joint space narrowing

1.05

1.03, 1.08

< 0.001

1.01

0.99, 1.03

0.264

1.02

1.01, 1.04

0.001

Methotrexate (yes)^a

1.37

0.67, 2.77

0.387

2.15

0.63, 7.33

0.222

1.47

0.82, 2.64

0.201

PsA duration

1.00

0.96, 1.04

0.816

1.03

0.97, 1.10

0.337

1.00

0.97, 1.04

0.896

Psoriasis duration

0.97

0.93, 0.998

0.039

1.03

0.99, 1.08

0.140

0.99

0.96, 1.01

0.277

Weight

1.01

0.99, 1.03

0.450

1.00

0.97, 1.03

0.848

1.00

0.99, 1.02

0.717